These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26718349)

  • 1. The Effectiveness of Zolpidem for the Treatment of Disorders of Consciousness.
    Tucker C; Sandhu K
    Neurocrit Care; 2016 Jun; 24(3):488-93. PubMed ID: 26718349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential benefits of zolpidem in disorders of consciousness.
    Noormandi A; Shahrokhi M; Khalili H
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):983-992. PubMed ID: 28649875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review.
    Bomalaski MN; Claflin ES; Townsend W; Peterson MD
    JAMA Neurol; 2017 Sep; 74(9):1130-1139. PubMed ID: 28655027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Arousal and Motor Function Using Zolpidem in a Patient With Space-Occupying Intracranial Lesions: A Case Report.
    Bomalaski MN; Smith SR
    PM R; 2017 Aug; 9(8):831-833. PubMed ID: 28093373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study.
    Thonnard M; Gosseries O; Demertzi A; Lugo Z; Vanhaudenhuyse A; Bruno MA; Chatelle C; Thibaut A; Charland-Verville V; Habbal D; Schnakers C; Laureys S
    Funct Neurol; 2013; 28(4):259-64. PubMed ID: 24598393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness.
    Gosseries O; Charland-Verville V; Thonnard M; Bodart O; Laureys S; Demertzi A
    Curr Pharm Des; 2014; 20(26):4167-84. PubMed ID: 24025057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically significant response to zolpidem in disorders of consciousness secondary to anti-N-methyl-D-aspartate receptor encephalitis in a teenager: a case report.
    Appu M; Noetzel M
    Pediatr Neurol; 2014 Mar; 50(3):262-4. PubMed ID: 24417935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological modulation of the state of awareness in patients with disorders of consciousness: an overview.
    Mura E; Pistoia F; Sara M; Sacco S; Carolei A; Govoni S
    Curr Pharm Des; 2014; 20(26):4121-39. PubMed ID: 24025054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zolpidem and restoration of consciousness--fact or fiction?
    Venter A
    S Afr Med J; 2015 Oct; 105(10):798. PubMed ID: 26636148
    [No Abstract]   [Full Text] [Related]  

  • 10. Zolpidem and restoration of consciousness.
    Whyte J; Rajan R; Rosenbaum A; Katz D; Kalmar K; Seel R; Greenwald B; Zafonte R; Demarest D; Brunner R; Kaelin D
    Am J Phys Med Rehabil; 2014 Feb; 93(2):101-13. PubMed ID: 24434886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotransmitters in disorders of consciousness and brain damage.
    Clauss RP
    Med Hypotheses; 2011 Aug; 77(2):209-13. PubMed ID: 21549512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of clinically significant responses to zolpidem among patients with disorders of consciousness: a preliminary placebo controlled trial.
    Whyte J; Myers R
    Am J Phys Med Rehabil; 2009 May; 88(5):410-8. PubMed ID: 19620954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Awakenings and awareness recovery in disorders of consciousness: is there a role for drugs?
    Pistoia F; Mura E; Govoni S; Fini M; Sarà M
    CNS Drugs; 2010 Aug; 24(8):625-38. PubMed ID: 20658796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analysis of the effects of using Zolpidem and an innovative multimodal interdisciplinary team approach in prolonged disorders of consciousness (PDOC).
    Delargy M; O'Connor R; McCann A; Galligan I; Cronin H; Gray D; O'Toole C
    Brain Inj; 2019; 33(2):242-248. PubMed ID: 30380923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel use of zolpidem in cerebellar mutism syndrome.
    Shyu C; Burke K; Souweidane MM; Dunkel IJ; Gilheeney SW; Gershon T; Khakoo Y
    J Pediatr Hematol Oncol; 2011 Mar; 33(2):148-9. PubMed ID: 21285896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood-brain barrier integrity in a zolpidem-responder patient.
    Nyakale NE; Clauss RP; Nel HW; Sathekge MM
    S Afr Med J; 2012 Jul; 102(10):790-1. PubMed ID: 23034205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disorders of consciousness after severe brain injury: therapeutic options.
    Schnakers C; Monti MM
    Curr Opin Neurol; 2017 Dec; 30(6):573-579. PubMed ID: 28901969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical complications during inpatient rehabilitation among patients with traumatic disorders of consciousness.
    Whyte J; Nordenbo AM; Kalmar K; Merges B; Bagiella E; Chang H; Yablon S; Cho S; Hammond F; Khademi A; Giacino J
    Arch Phys Med Rehabil; 2013 Oct; 94(10):1877-83. PubMed ID: 23735519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotransmitters in coma, vegetative and minimally conscious states, pharmacological interventions.
    Clauss RP
    Med Hypotheses; 2010 Sep; 75(3):287-90. PubMed ID: 20347531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive effect of cerebrolysin and amantadine on disorders of consciousness secondary to acquired brain injury: A retrospective case-control study.
    Lee S; Lee HH; Lee Y; Lee J
    J Rehabil Med; 2020 Feb; 52(2):jrm00025. PubMed ID: 32057086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.